Trial Profile
Open-label, multicenter phase IV study of ribavirin (Copegus) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients with chronic hepatitis C.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Ribavirin (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ANECO
- Sponsors Roche
- 26 Apr 2014 New source identified and integrated (EudraCT: 2011-001256-10)
- 31 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Aug 2013 Planned End Date changed from 1 Jul 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.